Zobrazeno 1 - 5
of 5
pro vyhledávání: '"C. Garaballu"'
Autor:
Iustina Janta, B. Serrano, J. C. Nieto, T. del Río, J. Lopez Longo, Amparo López, J.C. Sanchez, C. Garaballu, Indalecio Monteagudo, J. Martínez Barrio, C. Gonzalez, Felipe García
Publikováno v:
Osteoarthritis.
Background Denosumab (DNS) is a human monoclonal antibody directed against RANKL, which blocks the maturation of the osteoclast, inhibiting bone resorption. The binding of DNS to RANKL suppresses bone resorption mediated by osteoclasts and decreases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff8bb24c7e3ff6c4db200cffedd9e6a7
https://doi.org/10.1136/annrheumdis-2018-eular.5531
https://doi.org/10.1136/annrheumdis-2018-eular.5531
Autor:
A Lopez Esteban, F. Garcia, I. Janta, J.G. Ovalles, B. Serrano, J.C. Sanchez, C. Garaballu, C. Gonzalez, T. Del Rio, J. Lopez Longo, I. Monteagudo, J.C. Nieto
Publikováno v:
Saturday, 16 JUNE 2018.
Background Biological therapies (BT) have changed the prognosis of chronic arthritis (CA); however, they have associated the increased risk of infections. Denosumab (DNS) is the first biologic approved for the treatment of osteoporosis (OP) and is al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e8592b297e00e7f473493c9d2fec312
https://doi.org/10.1136/annrheumdis-2018-eular.6428
https://doi.org/10.1136/annrheumdis-2018-eular.6428
Autor:
C. Garaballu, Iustina Janta, C Barbero, T. del Río, J. C. Nieto González, J. Lopez Longo, Indalecio Monteagudo, Felipe García, A. Lόpez Esteban, C. Gonzalez
Publikováno v:
Poster Presentations.
Background Inflammatory arthropathies are a group of diseases that have common characteristics, like unknown etiology, autoimmune or autoinflammatory pathogenesis, genetic predisposition and chronicity. These affect people of all ages and can cause p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fdc619d9625f26ab7aab943e72c85e7
https://doi.org/10.1136/annrheumdis-2017-eular.4938
https://doi.org/10.1136/annrheumdis-2017-eular.4938
Autor:
A. Beltrán, J. C. Nieto González, Cristina González, Iustina Janta, F. Garcia Calle, A. Lopez Esteban, T. del Río, E. Naredo, C. Garaballu, Maria D. Ramos, Francisco Javier López-Longo, Indalecio Monteagudo
Publikováno v:
Annals of the Rheumatic Diseases. 75:1299.1-1299
Background The development of biological therapies (BT) represented an important advancement in the treatment of patients with inflammatory arthritis. These treatments have proven to be effective in controlling disease activity, leading to clinical r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e83e95ba3916cba490a00fd0734c810
https://doi.org/10.1136/annrheumdis-2016-eular.4183
https://doi.org/10.1136/annrheumdis-2016-eular.4183
Autor:
F. Garcia Calle, E. Naredo, Juan Carlos Nieto-González, Iustina Janta, T. del Río, S. García Linde, M.D.C. Ramos Pinilla, A. Beltrán Lόpez, C. Garaballu, Macarena Rodriguez, Luis Carreño, A. Lόpez Esteban
Publikováno v:
Annals of the Rheumatic Diseases. 74:530.4-531
Background Osteoporosis is a common disease consisting of reduced bone mineral density, with a raised fracture risk. Denosumab is the first fully human monoclonal antibody, binding RANK-L, approved for postmenopausal osteoporosis with high fracture r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a6a06ee425d9c81429f78662c91140d
https://doi.org/10.1136/annrheumdis-2015-eular.4709
https://doi.org/10.1136/annrheumdis-2015-eular.4709